| European And Developing Countries Clinical Trials Partnership |
Article Index for European |
Website Links For European |
Information About ™European And Developing Countries Clinical Trials Partnership |
| CATEGORIES ABOUT EUROPEAN AND DEVELOPING COUNTRIES CLINICAL TRIALS PARTNERSHIP | |
| clinical research | |
| international health organizations | |
| multiregional international organizations | |
| health organizations | |
| SHOPPER'S DELIGHT | |
BACKGROUND The EDCTP is a partnership between the , the G8 , and the African Union , and the program envisioned the provision of €600 million for the period 2003 - 2007 in order to translate medical research results into clinical applications relevant to the needs of developing countries. The stance on access to essential medicines. {Link without Title} The second EDCTP Annual Forum was held in Durban, South Africa , on 7 - 9 October 2005 . PROJECTS AND ACTIVITIES A number of different partnership activities have been proposed:
Partnerships among the EU and associated countries, allowing focused collaboration of national and European efforts that were not previously coordinated.
Partnerships among EU and developing countries that focuses specifically on developing countries' needs, who are jointly involved in setting the research priorities.
Efforts aimed at creating lasting long-term partnerships between African scientists and research institutions in Africa.
Effective cooperation and coordination with other international organisations (''see Member states and participants'' section, below).
Manifested as a general strengthening of clinical research capacity in Africa, including training activities, workshops and meetings, and the upgrading of Clinical Trial sites in Africa. FUNDING ] The total budget of the EDCTP is €600 million for the period 2003 - 2007 , of which one third (€200 million) is to be provided by the EU budget, an equivalent amounts from Member States' activities, and the remaining €200 million from industry, charities, and private organisations. The Partnership is intended to be a long-term initiative (10-20 years) and a separate legal entity has been created to maintain its independence and flexibility. Taken together, clinical trials based in developing countries where the diseases are endemic, capacity building, and South-South networking are expected to make up over 90% of the overall budget. (figure). MEMBER STATES AND PARTICIPANTS {LINK WITHOUT TITLE}
: EU member states, plus Norway and Switzerland .
: All sub-Saharan African countries.
: Industry interest has been expressed by (amongst others) GSK , Chiron , Aventis Pasteur , and Sanofi-Aventis .
: The World Health Organisation (WHO-TDR) (http://www.who.int/tdr/) : The Global Fund to fight HIV/AIDS, Tuberculosis and Malaria (GFATM) (http://www.theglobalfund.org/) : The Global Alliance For Vaccines And Immunization (GAVI) (http://www.vaccinealliance.org/) : The International Aids Vaccine Initiative (IAVI) (http://www.iavi.org/) : The European Malaria Vaccine Initiative (EMVI) (http://www.emvi.org/) : The Malaria Vaccine Initiative (MVI) (http://www.malariavaccine.org/) : Stop TB Partnership (Stop TB) (http://www.stoptb.org/) : The National Institutes Of Health (NIH) (http://www.nih.gov/)
: The Wellcome Trust : The Bill And Melinda Gates Foundation REPRESENTATIVES High representative - Pascoal Mocumbi Executive director - Leroy |